| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/10/2013 | CA2853799A1 Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| 05/10/2013 | CA2853723A1 N-(pyrid-4-yl)amides and n-(pyrimidin-4-yl)amides and their pharmaceutical and cosmetic use |
| 05/10/2013 | CA2853655A1 Compositions and methods for hemostasis |
| 05/10/2013 | CA2853582A1 2-carboxamide cycloamino urea derivatives for use in treating vegf - dependent diseases |
| 05/10/2013 | CA2853581A1 Pesticidal compounds |
| 05/10/2013 | CA2853495A1 Methods and compositions for treating hepatitis c virus |
| 05/10/2013 | CA2853491A1 Methods for treatment of diseases and disorders related to transducin .beta.-like protein 1 (tbl1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia |
| 05/10/2013 | CA2853454A1 Aminopyrimidine kinase inhibitors |
| 05/10/2013 | CA2853439A1 Benzenesulfonamide compounds and their use as therapeutic agents |
| 05/10/2013 | CA2853325A1 Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitors |
| 05/10/2013 | CA2853299A1 Use of (n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide) for treating cftr mediated diseases |
| 05/10/2013 | CA2853282A1 Nicotinic receptor non-competitive modulators |
| 05/10/2013 | CA2853235A1 Ophthalmological aqueous composition |
| 05/10/2013 | CA2853233A1 Ophthalmological aqueous composition |
| 05/10/2013 | CA2853006A1 Substituted benzylamine compounds, their use in medicine, and in particular the treatment of hepatitis c virus (hcv) infection |
| 05/10/2013 | CA2852964A1 Bicyclic piperazine compounds |
| 05/10/2013 | CA2852700A1 Rod-like hepatitis c virus inhibitors containing the fragment {2-[4-(biphenyl-4-yl)-1h-imidazo-2-yl]pyrrolidine-1-carbonlymethyl}amine |
| 05/10/2013 | CA2852490A1 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same |
| 05/10/2013 | CA2852000A1 Crystalline and non-crystalline forms of sglt2 inhibitors |
| 05/10/2013 | CA2851996A1 Pharmaceutical compositions for substituted quinazolinones |
| 05/10/2013 | CA2851327A1 Pharmaceutical composition of omeprazole |
| 05/10/2013 | CA2851296A1 Methods and compositions for neuroprotection |
| 05/10/2013 | CA2851095A1 A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent |
| 05/10/2013 | CA2850955A1 Pharmaceutical compositions of hydrophobic camptothecin derivatives |
| 05/10/2013 | CA2850953A1 Neprilysin inhibitors |
| 05/10/2013 | CA2850516A1 Substituted pyrazole analogues as rar antagonists |
| 05/10/2013 | CA2849945A1 New aryl-quinoline derivatives |
| 05/10/2013 | CA2849194A1 Imidazopyridazine compounds |
| 05/10/2013 | CA2848824A1 Azetidine compounds, compositions and their use as inhibitors of soluble epoxide hydrolase |
| 05/10/2013 | CA2846454A1 Synergistic combinations of pi3k- and mek-inhibitors |
| 05/10/2013 | CA2846074A1 Compositions and methods for treatment of metastatic cancer |
| 05/10/2013 | CA2843417A1 Treatment of breast cancer |
| 05/10/2013 | CA2795416A1 Mitochondria-targeted inhibitors of cytochrome c peroxidase for protection from apoptosis |
| 05/10/2013 | CA2757917A1 Mitochondria-targeted inhibitors of cytochrome c peroxidase for protection from apoptosis |
| 05/09/2013 | US20130116586 Use of dronedarone or a pharmaceutically acceptable salt thereof for the preparation of a drug for the prevention of atrial fibrillation |
| 05/09/2013 | US20130116337 Methods and compositions for treating conditions mediated by oxidative stress or electrophilic environmental toxins |
| 05/09/2013 | US20130116336 Treatment of ataxia telangiectasia |
| 05/09/2013 | US20130116335 Method for identifying therapeutic agents for treatment of cancer |
| 05/09/2013 | US20130116334 Treatment of Irritable Bowel Syndrome |
| 05/09/2013 | US20130116333 Solid tapentadol in non-crystalline form |
| 05/09/2013 | US20130116332 Formulations, salts and polymorphs of transnorsertraline and uses thereof |
| 05/09/2013 | US20130116331 Medical gel |
| 05/09/2013 | US20130116329 Treatment for Reducing Inflammation |
| 05/09/2013 | US20130116326 Treatment of delayed cutaneous hypersensitivity conditions with s-farnesylthiosalicylic acid and analogs thereof |
| 05/09/2013 | US20130116325 Compositions and methods for treating anhidrosis |
| 05/09/2013 | US20130116324 Pharmaceutical composition for the prevention or treatment of inflammatory diseases or immune diseases containing ramalin |
| 05/09/2013 | US20130116323 Methods of improving or preserving lung function in a patient with a pulmonary disorder |
| 05/09/2013 | US20130116322 Alkenyl naphthylacetic acids |
| 05/09/2013 | US20130116321 Composition containing serine as an active ingredient for the prevention and treatment of fatty liver diseases, and the use thereof |
| 05/09/2013 | US20130116320 Gastric retentive gabapentin dosage forms and methods for using same |
| 05/09/2013 | US20130116318 Enzyme Inhibitors |
| 05/09/2013 | US20130116317 Furanyl compounds and the use thereof |
| 05/09/2013 | US20130116316 Solid Pharmaceutical Compositions Containing Benzofuran Derivatives |
| 05/09/2013 | US20130116315 Composition for the prevention or treatment of obesity, dyslipidaemia, fatty liver or insulin resistance syndrome, comprising piperonal as an active ingredient |
| 05/09/2013 | US20130116314 Method of maintaining or improving the skin health of an animal comprising administering as a dietary supplement a composition comprising flax seed oil and gamma linolenic acid |
| 05/09/2013 | US20130116313 Compositions and Methods for Inhibiting G Protein Signaling |
| 05/09/2013 | US20130116312 Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging |
| 05/09/2013 | US20130116309 Oligomeric compounds for the modulation of hif-1a expression |
| 05/09/2013 | US20130116308 Cd36 inhibition to control obesity and insulin sensitivity |
| 05/09/2013 | US20130116302 Pharmaceutical composition for the treatment of chlamydial infection |
| 05/09/2013 | US20130116300 Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1 |
| 05/09/2013 | US20130116298 Antitumor agent or postoperative adjuvant chemotherapeutic agent for hepatocellular carcinoma treatment |
| 05/09/2013 | US20130116293 High-Throughput Methods for Determining Pharmacological Levels of Plasma D-Serine |
| 05/09/2013 | US20130116292 Neurorestoration with r(+) pramipexole |
| 05/09/2013 | US20130116291 Association of xanthine oxidase inhibitors and statins and use thereof |
| 05/09/2013 | US20130116290 Use of Dipeptidyl Peptidase IV Effectors for Normalizing the Blood Glucose Level in Mammals |
| 05/09/2013 | US20130116289 5-(biphenyl-4-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate(sip)receptors |
| 05/09/2013 | US20130116286 Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension |
| 05/09/2013 | US20130116285 Chemical Compounds |
| 05/09/2013 | US20130116284 Lipoic acid and nitroxide derivatives and uses thereof |
| 05/09/2013 | US20130116282 Buckwheat extract enriched in d-fagomine |
| 05/09/2013 | US20130116281 Multiphoton Activable Quinoline Derivatives, Their Preparation and Their Uses |
| 05/09/2013 | US20130116279 Bicyclic heteroaryl inhibitors of pde4 |
| 05/09/2013 | US20130116278 Antimicrobial agents |
| 05/09/2013 | US20130116276 New use of neferine |
| 05/09/2013 | US20130116274 Therapeutic combinations containing riluzole |
| 05/09/2013 | US20130116273 Beta carboline derivatives useful in the treatment of proliferative disorders |
| 05/09/2013 | US20130116272 Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators |
| 05/09/2013 | US20130116271 Tacrolimus-containing oil-in-water type creamy composition |
| 05/09/2013 | US20130116268 Use of modified pyrimidine compounds to promote stem cell migration and proliferation |
| 05/09/2013 | US20130116267 Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication |
| 05/09/2013 | US20130116266 Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| 05/09/2013 | US20130116263 Pak inhibitors for the treatment of cell proliferative disorders |
| 05/09/2013 | US20130116262 Bicyclic piperazine compounds |
| 05/09/2013 | US20130116260 Fused heteroaromatic pyrrolidinones as syk inhibitors |
| 05/09/2013 | US20130116259 Combination therapy for treating or preventing an inflammatory skin disorder |
| 05/09/2013 | US20130116257 Method for treating a pulmonary hypertension condition |
| 05/09/2013 | US20130116255 Combination of brimonidine and timolol for topical ophthalmic use |
| 05/09/2013 | US20130116254 Compositions and methods for lowering intraocular pressure |
| 05/09/2013 | US20130116250 Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof |
| 05/09/2013 | US20130116249 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof |
| 05/09/2013 | US20130116247 IRE-1alpha INHIBITORS |
| 05/09/2013 | US20130116246 8-fluorophthalazin-1(2h)-one compounds |
| 05/09/2013 | US20130116245 Alkylated piperazine compounds |
| 05/09/2013 | US20130116243 Inhibitors of akt activity |
| 05/09/2013 | US20130116242 Method of treatment of hormone depletion induced vasomotor |
| 05/09/2013 | US20130116238 Modulators of atp-binding cassette transporters |
| 05/09/2013 | US20130116237 [6,6] and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists |
| 05/09/2013 | US20130116235 Heteroaryl pyridone and aza-pyridone compounds |
| 05/09/2013 | US20130116234 Aryl-quinoline derivatives |